ONEpossible 2023

Published on May 31, 2023

 

 

Recently published findings show the long-term benefits of lonafarnib have increased life expectancy by 35%!

 

Thanks to YOU, PRF continues to make a dramatic impact on the length and quality of life for those with Progeria!

PRF co-founder and Medical Director, Dr. Leslie Gordon led a study* published in the world’s top cardiovascular journal, Circulation, showing that the longer those with Progeria stayed on lonafarnib, the greater the survival rate. Those who’ve taken it for 10+ years have an average 5-year, or 35%, increase in life expectancy.

Hot off the presses: Dr. Gordon sums up the profound impact this study will have on the Progeria community in a feature podcast just published TODAY by Circulation on the Run. Get it here! (Link available June 5th).

YOUR support got us to 35%

Please help us get to the CURE!

Donate today and be ONE to make the cure POSSIBLE!

2023 ONEpossible Teams

Team Brennen

 

Team Kaylee

 

Team Nathan & Bennett

 

Team PRF

 

Team Zoey

 

 

*Gordon, L.B., Norris, W., Hamren, S., et al. Plasma Progerin in Patients with Hutchinson-Gilford Progeria Syndrome: Immunoassay Development and Clinical Evaluation. Circulation, 2023

The post ONEpossible 2023 appeared first on The Progeria Research Foundation.

Continue reading on website
Other news

Team PRF runs the Boston Marathon again!

April 6, 2023
On Monday, April 17, 2023, The Progeria Research Foundation will cheer on two long-time PRF supporters who will take to the streets in the Boston Marathon on behalf of the Progeria community: Paul Michienzie from Foxboro (right) and Bobby Nadeau (left) from Mansfield. The good friends will take on the coveted 26.2-mile course to raise funds toward the cure for Progeria.Paul is running the marathon

PRF co-founder serves as thought leader in rare disease drug development

July 25, 2023
PRF’s co-founder and Medical Director, Dr. Leslie Gordon, was recently invited to contribute to an educational video series produced by the National Organization for Rare Disorders (NORD), along with her colleague Dr. Francis Collins, Science Advisor to the President of the U.S. and former Director of the National Institutes of Health (NIH).The two were asked to share learnings from their experien